Dan Schell articles

Bayer Launches Investigator-Sponsored Collaborative Studies 11/10/2023
Bayer added three Phase 3 trials to its MOONRAKER clinical development program for the study of Kerendia (finerenone) as a potential treatment for heart failure. Overall, the goal for the program is to enroll 15,000 participants.

This website uses cookies to ensure you get the best experience on our website. Learn more